rb1  (Cell Signaling Technology Inc)

Journal: Nature Communications

Article Title: Supercharging-enhanced nDIA-MS enables global profiling of drug-induced proteome solubility shifts

doi: 10.1038/s41467-026-69025-8

Figure Lengend Snippet: A Scatter plots showing the proteins modulated by sole treatment of both MG132 (x-axis) and ML-792 (y-axis) from three cancer cell lines. Only proteins with p -values below 0.05 are displayed. B Scatter plots showing the proteins modulated by sole treatment of MG132 (x-axis) and subsequent treatment of ML-792 (y-axis) from three cell lines. Only proteins with p-values below 0.05 are displayed. ( C ) Scatter plots showing the proteins modulated by sole treatment of ML-792 (x-axis) and subsequent treatment of MG-132 (y-axis) from three cell lines. Only proteins with p -values below 0.05 are displayed. D–G Western blotting results of representative proteins that modulated by MG132 or ML792, including NAB2, RAD54L2, SMAD2, and RB1. Experiments were repeated at least three times, and similar results were obtained. Source data are provided as a Source Data file.

Article Snippet: Antibodies used in this study included SUMO-2/3 (4971S; Cell Signaling Technology), SMAD2 (3103 T; Cell Signaling Technology), RB1 (9309 T; Cell Signaling Technology), EGR1 (4153 T; Cell Signaling Technology), NAB2 (sc-23867, Santa Cruz Biotechnology), SP100 (GTX131569, GeneTex), DAXX (4533 T; Cell Signaling Technology), c-Fos (2250 T; Cell Signaling Technology), HSF1 (4356 T; Cell Signaling Technology), CYR61 (14479 T; Cell Signaling Technology), CTGF (86641 T; Cell Signaling Technology), BAG6 (8523S; Cell Signaling Technology), UBL4A (14253-1-AP, Proteintech), TEX264 (NBP1-89866, Novus Biologicals), POLR3G (24701-1-AP, Proteintech), HIF1A (14179 T; Cell Signaling Technology), ATR (2790S; Cell Signaling Technology), Ubiquitin (58295S; Cell Signaling Technology), REV1 (sc-393022, Santa Cruz).

Techniques: Western Blot

Journal: Cell Death & Disease

Article Title: Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells

doi: 10.1038/s41419-025-08362-w

Figure Lengend Snippet: A Proliferation of MIA PaCa-2 cells measured by automated transmission microscopy (Celigo®). Cells were reverse transfected by siRNAs to RB1 ( A ), RBL1 ( B ), RBL2 ( C ), E2F4 ( D ), or FOS ( E ); (scrb = ctrl siRNA). On day 1 after transfection, the cells were treated with DMSO, 10 µM (5 µM for ( E )) Palbociclib, 5 µM Sotorasib or the combination, for 48 h, followed by 7 days of recovery in normal medium. Means of three technical replicates ±SD. F MIA PaCa-2 cells were transfected by siRNAs to deplete CDKN1B ( F – H ) or control siRNA (scrb) during seeding. On day 1, the cells were treated with 1, 2.5, or 5 µM Palbociclib, with or without 5 µM Sotorasib, 48 h, followed by seven days of recovery without drugs. Three technical replicates, means ± SD. I Proliferation of 8661 cells (murine PDAC) wild type (WT) or CDKN1B knock-out (KO) lines (n = 3 clones, 3 technical replicates each). All cells were treated and observed as in ( A ), with the following specifics: 1 µM Palbociclib, 0.1 µM MRTX1133 or the combination. J Cell viability of 8661 WT and CDKN1B KO cells evaluated at D3 and D7 corresponding to ( I ). Statistical analyses: A – J unpaired t-test ( A – I of AUC); ns not significant, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. Complete statistics in Supplementary Fig. .

Article Snippet: RB1 (4H1) , Cell Signaling , Cat# 9309; RRID: AB_823629.

Techniques: Transmission Assay, Microscopy, Transfection, Control, Knock-Out, Clone Assay